A J Garber

Summary

Affiliation: Texas Medical Center
Country: USA

Publications

  1. ncbi request reprint Premixed insulin analogues for the treatment of diabetes mellitus
    Alan J Garber
    Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Drugs 66:31-49. 2006
  2. doi request reprint Obesity and type 2 diabetes: which patients are at risk?
    A J Garber
    Departments of Medicine, Biochemistry and Molecular Biology, and Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA
    Diabetes Obes Metab 14:399-408. 2012
  3. doi request reprint Postprandial dysmetabolism and the heart
    Alan J Garber
    Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Baylor College of Medicine, 1709 Dryden Road, Houston, TX 77030, USA
    Heart Fail Clin 8:563-73. 2012
  4. doi request reprint Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
    Alan J Garber
    Baylor College of Medicine, Houston, TX, USA
    Lancet 379:1498-507. 2012
  5. doi request reprint Liraglutide in oral antidiabetic drug combination therapy
    A J Garber
    Division of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, Houston, TX 77030, USA
    Diabetes Obes Metab 14:13-9. 2012
  6. ncbi request reprint Cardiovascular risk and diabetes mellitus management: diagnosis and treatment in special patient populations. Introduction
    Alan J Garber
    Department of Medicine, Baylor College of Medicine, 6550 Fannin, Suite 1045, Houston, Texas 77030, USA
    Am J Med 118:1S-2S. 2005
  7. ncbi request reprint Pharmacologic modifications of hormones to improve their therapeutic potential for diabetes management
    Alan J Garber
    Department of Medicine, Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA
    Diabetes Obes Metab 7:666-74. 2005
  8. ncbi request reprint Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study)
    A J Garber
    Baylor College of Medicine, Houston, TX 77030, USA
    Diabetes Obes Metab 8:58-66. 2006
  9. ncbi request reprint Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study
    A J Garber
    Division of Endocrinology, Baylor College of Medicine, Houston, TX 77030, USA
    Diabetes Obes Metab 9:166-74. 2007
  10. ncbi request reprint Premixed insulin treatment for type 2 diabetes: analogue or human?
    Alan J Garber
    Baylor College of Medicine, Faculty Center, Houston, TX 77030, USA
    Diabetes Obes Metab 9:630-9. 2007

Detail Information

Publications43

  1. ncbi request reprint Premixed insulin analogues for the treatment of diabetes mellitus
    Alan J Garber
    Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Drugs 66:31-49. 2006
    ..In addition, given the convenience of mealtime dose administration, compliance with insulin therapy may increase with premixed insulin analogues...
  2. doi request reprint Obesity and type 2 diabetes: which patients are at risk?
    A J Garber
    Departments of Medicine, Biochemistry and Molecular Biology, and Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA
    Diabetes Obes Metab 14:399-408. 2012
    ..By viewing obesity as a metabolic disorder rather than a personal weakness, we can work with patients to address this increasingly prevalent condition and improve long-term health outcomes...
  3. doi request reprint Postprandial dysmetabolism and the heart
    Alan J Garber
    Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Baylor College of Medicine, 1709 Dryden Road, Houston, TX 77030, USA
    Heart Fail Clin 8:563-73. 2012
    ..Pharmacotherapies that target postprandial hyperglycemia and/or postprandial dyslipidemia are likely to improve endothelial function, which may have positive implications for cardiovascular outcomes...
  4. doi request reprint Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
    Alan J Garber
    Baylor College of Medicine, Houston, TX, USA
    Lancet 379:1498-507. 2012
    ..Insulin degludec is a new, ultra-longacting basal insulin. We aimed to assess efficacy and safety of insulin degludec compared with insulin glargine in patients with type 2 diabetes mellitus...
  5. doi request reprint Liraglutide in oral antidiabetic drug combination therapy
    A J Garber
    Division of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, Houston, TX 77030, USA
    Diabetes Obes Metab 14:13-9. 2012
    ..While further study will be required, GLP-1 receptor agonists may offer important advantages over other diabetic therapies, including DPP-4 inhibitors...
  6. ncbi request reprint Cardiovascular risk and diabetes mellitus management: diagnosis and treatment in special patient populations. Introduction
    Alan J Garber
    Department of Medicine, Baylor College of Medicine, 6550 Fannin, Suite 1045, Houston, Texas 77030, USA
    Am J Med 118:1S-2S. 2005
  7. ncbi request reprint Pharmacologic modifications of hormones to improve their therapeutic potential for diabetes management
    Alan J Garber
    Department of Medicine, Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA
    Diabetes Obes Metab 7:666-74. 2005
    ..In summary, the development of new insulin and other hormone preparations by the manipulation of native peptide structure has recently improved our antidiabetic armamentarium, and further research will continue this fruitful approach...
  8. ncbi request reprint Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study)
    A J Garber
    Baylor College of Medicine, Houston, TX 77030, USA
    Diabetes Obes Metab 8:58-66. 2006
    ..5 and <7%)...
  9. ncbi request reprint Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study
    A J Garber
    Division of Endocrinology, Baylor College of Medicine, Houston, TX 77030, USA
    Diabetes Obes Metab 9:166-74. 2007
    ..The purpose of this study was to assess the efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor vildagliptin in combination with the thiazolidinedione (TZD) pioglitazone in patients with type 2 diabetes (T2DM)...
  10. ncbi request reprint Premixed insulin treatment for type 2 diabetes: analogue or human?
    Alan J Garber
    Baylor College of Medicine, Faculty Center, Houston, TX 77030, USA
    Diabetes Obes Metab 9:630-9. 2007
    ..Overall, the evidence suggests that premixed insulin analogues are cost effective and have useful advantages over premixed human insulin for the treatment of type 2 diabetes...
  11. ncbi request reprint Lower risk of hypoglycemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase III trials
    Alan J Garber
    Division of Diabetes, Endocrinology and Metabolism, Baylor College of Medicine, Houston, Texas, USA
    J Am Geriatr Soc 55:1735-40. 2007
    ..To compare the safety and efficacy of insulin detemir with that of neutral protamine Hagedorn (NPH) insulin in older (aged >/=65) and younger (aged 18-64) persons with type 2 diabetes mellitus (DM)...
  12. pmc Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes
    A Garber
    Department of Medicine and the Division of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, 1709 Dryden Road, Houston, TX 77030, USA
    Diabetes Obes Metab 13:348-56. 2011
    ..Most treatments for type 2 diabetes fail over time, necessitating combination therapy. We investigated the safety, tolerability and efficacy of liraglutide monotherapy compared with glimepiride monotherapy over 2 years...
  13. ncbi request reprint The metabolic syndrome
    Alan J Garber
    Department of Medicine, Baylor College of Medicine, 6550 Fannin Street, Suite 1045, Houston, TX 77030, USA
    Med Clin North Am 88:837-46, ix. 2004
    ..A combination of chemoprevention and lifestyle modification may prevent many if not most cases of diabetes if treatment is instituted early...
  14. ncbi request reprint Metformin and vascular protection: a diabetologist's view
    A J Garber
    Baylor College of Medicine and The Methodist Hospital, Houston, Texas 77030, USA
    Diabetes Metab 29:6S113-6. 2003
    ....
  15. ncbi request reprint Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes
    A J Garber
    Baylor College of Medicine and The Methodist Hospital, Houston, Texas 77030, USA
    Diabetes Obes Metab 4:201-8. 2002
    ..To evaluate whether simultaneous initial treatment of both insulin resistance and impaired beta-cell insulin secretion with glyburide/metformin tablets is superior to monotherapy with each component agent...
  16. ncbi request reprint Benefits of combination therapy of insulin and oral hypoglycemic agents
    Alan J Garber
    Baylor College of Medicine, Houston, Tex 77030, USA
    Arch Intern Med 163:1781-2. 2003
  17. ncbi request reprint Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: an open-label extension study
    Alan J Garber
    Baylor College of Medicine, Methodist Hospital, Houston, Texas 77030, USA
    Clin Ther 24:1401-13. 2002
    ....
  18. ncbi request reprint Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes
    Alan J Garber
    Baylor College of Medicine and The Methodist Hospital, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 88:3598-604. 2003
    ....
  19. ncbi request reprint The importance of early insulin secretion and its impact on glycaemic regulation
    A J Garber
    Baylor College of Medicine, Houston, Texas 77030, USA
    Int J Obes Relat Metab Disord 24:S32-7. 2000
    ..As well as offering a more flexible approach to treatment, prandial repaglinide is associated with a reduced risk of severe hypoglycaemia...
  20. ncbi request reprint Influence of initial hyperglycaemia, weight and age on the blood glucose lowering efficacy and incidence of hypoglycaemic symptoms with a single-tablet metformin-glibenclamide therapy (Glucovance) in type 2 diabetes
    A Garber
    Baylor College of Medicine and The Methodist Hospital, Houston, Texas 77030, USA
    Diabetes Obes Metab 5:171-9. 2003
    ..25 mg, 500 mg/2.5 mg and 500 mg/5 mg), in comparison with metformin 500 mg and glibenclamide 2.5-5 mg monotherapy, in clinically important patient subgroups within the type 2 diabetic population...
  21. doi request reprint Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea
    A J Garber
    Baylor College of Medicine, Houston, TX, USA
    Diabetes Obes Metab 10:1047-56. 2008
    ..To compare the efficacy and tolerability of vildagliptin vs. placebo in patients with type 2 diabetes mellitus (T2DM) who are inadequately controlled [haemoglobin A(1c) (HbA(1c)) 7.5 to 11%] with prior sulphonylurea (SU) monotherapy...
  22. doi request reprint Methods to enhance delivery of prandial insulin and basal-prandial insulin
    A J Garber
    Department of Medicine, Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA
    Diabetes Obes Metab 15:11-7. 2013
    ....
  23. ncbi request reprint Diabetic dyslipidemia and the heart
    Abu R Vasudevan
    Center for Cadiovascular Disease Prevention, Lipoprotein and Atherosclerosis Research Section, Baylor College of Medicine, Houston, TX 77030, USA
    Heart Fail Clin 2:37-52. 2006
  24. ncbi request reprint Attenuating CV risk factors in patients with diabetes: clinical evidence to clinical practice
    Alan J Garber
    Baylor College of Medicine, Houston, Texas 77030, USA
    Diabetes Obes Metab 4:S5-12. 2002
    ..Data from the Heart Outcomes Prevention Evaluation (HOPE) trial demonstrated that CV risk can be further reduced by the addition of the ACE inhibitor ramipril to the existing treatment regimen of high-risk patients with diabetes...
  25. pmc The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone
    Ralph A DeFronzo
    University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
    Diabetes Care 32:1649-55. 2009
    ..This 24-week trial assessed the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes with inadequate glycemic control with metformin alone...
  26. ncbi request reprint Diabetes and vascular disease
    A J Garber
    Vascular Disease Working Group, 6550 Fannin Street, Suite 1045, Houston, TX 77030, USA
    Diabetes Obes Metab 2:S1-5. 2000
    ..Important steps to decreasing the risk of these diseases in diabetic patients are strict glycaemic control, control of hypertension, and modification of dyslipidaemia...
  27. ncbi request reprint Strategies for better diabetes control in the US
    A J Garber
    Department of Medicine, Baylor College of Medicine, and The Methodist Hospital, Houston, Texas 77030, USA
    Drugs 58:61-9. 1999
    ..It is hoped that organised implementation of these treatment algorithms will produce better control of diabetes and its complications than the current ad hoc strategies used by individual practitioners...
  28. ncbi request reprint Point: Inpatient glucose management: the emperor finally has clothes
    Michael Bryer-Ash
    Gonda Diabetes Center, Division of Endocrinology, Diabetes and Hypertension, David Geffen School of Medicine at UCLA, 900 Veteran Ave, Suite 24 130, Los Angeles, CA 90095, USA
    Diabetes Care 28:973-5. 2005
  29. ncbi request reprint Current standards of care for inpatient glycemic management and metabolic control: is it time for definite standards and targets?
    Alan J Garber
    Baylor College of Medicine, Houston, Texas, USA
    Endocr Pract 10:10-2. 2004
    ..To review the available literature on the presence of diabetes in the inpatient population and its effect on outcomes...
  30. ncbi request reprint An overview of incretin clinical trials
    Alan J Garber
    Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, Houston, TX, USA
    J Fam Pract 57:S10-8. 2008
    ..The article also discusses some of the important clinical differences between GLP-1 receptor agonists and DPP-4 inhibitors...
  31. ncbi request reprint Role of insulin signaling in maintaining energy homeostasis
    Morali D Sharma
    Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, Houston, Texas 77030, USA
    Endocr Pract 14:373-80. 2008
    ..To examine the role that insulin signaling plays in modulating metabolic functions involving both peripheral and hypothalamic systems...
  32. ncbi request reprint Update: vildagliptin for the treatment of Type 2 diabetes
    Alan J Garber
    Professor of Medicine, Biochemistry and Molecular Biology, and Molecular and Cellular Biology, Baylor College of Medicine, Division of Diabetes, Endocrinology and Metabolism, 1709 Dryden, Suite 1000, Houston, TX 77030, USA
    Expert Opin Investig Drugs 17:105-13. 2008
    ..Across studies, vildagliptin was effective in reducing HbA(1c), had a low risk of hypoglycemia and was weight-neutral and well tolerated...
  33. ncbi request reprint Insulin resistance syndrome. A review
    A R Vasudevan
    Division of Endocrinology, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
    Minerva Endocrinol 30:101-19. 2005
    ..The rising obesity epidemic portends great significance, as it is associated with a high prevalence of IR. We review the etiopathogenesis of IR, the clinical spectrum, and review the clinical data on the management of IR...
  34. ncbi request reprint Treatment of dyslipidemia in diabetes
    A J Garber
    Departments of Medicine, Biochemistry and Cell Biology, Department of Family and Community, Baylor College of Medicine, Department of Endocrinology, Diabetes, and Metabolism, Methodist Hospital, Houston, Texas, USA
    Endocrinol Metab Clin North Am 30:999-1010. 2001
    ..Statins are also the only agents thus far shown in prospective, controlled trials to reduce the risk of coronary events in diabetic patients definitively...
  35. ncbi request reprint Achievement of insulin independence in three consecutive type-1 diabetic patients via pancreatic islet transplantation using islets isolated at a remote islet isolation center
    John A Goss
    Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA
    Transplantation 74:1761-6. 2002
    ....
  36. ncbi request reprint Cardiovascular complications of diabetes: prevention and management
    Alan J Garber
    Baylor College of Medicine, Methodist Hospital Houston, Texas, USA
    Clin Cornerstone 5:22-37. 2003
    ..For the most part, such management has been proven to reduce CV events in patients with diabetes, particularly type 2 diabetes...
  37. ncbi request reprint Reducing the risk of stroke through appropriate targets and treatments
    Michael H Davidson
    Prev Cardiol 10:215-21. 2007
    ....
  38. ncbi request reprint American College of Endocrinology position statement on inpatient diabetes and metabolic control
    Alan J Garber
    Endocr Pract 10:4-9. 2004
  39. ncbi request reprint American College of Endocrinology position statement on inpatient diabetes and metabolic control
    Alan J Garber
    Endocr Pract 10:77-82. 2004
  40. ncbi request reprint New standards to reduce morbidity and mortality in hospitalized patients with diabetes
    Alan J Garber
    Am Fam Physician 73:591, 594. 2006
  41. ncbi request reprint Assessing the role of biphasic insulin aspart 30 as an effective and tolerable front-line therapy for type 2 diabetes
    Alan J Garber
    Clin Ther 27:S39-41. 2005
  42. ncbi request reprint Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin
    Emanuele Bosi
    Diabetes and Endocrinology Unit, Department of General Medicine, San Raffaele Scientific Institute, Vita Salute San Raffaele University, Milan, Italy
    Diabetes Care 30:890-5. 2007
    ..We sought to evaluate the efficacy and safety of vildagliptin, a new dipeptidyl peptidase-4 inhibitor, added to metformin during 24 weeks of treatment in patients with type 2 diabetes...
  43. ncbi request reprint The metabolic syndrome: a call to action
    Antonio M Gotto
    Office of the Dean, Joan and Sanford I Weill Medical College of Cornell University, New York, New York, USA
    Coron Artery Dis 17:77-80. 2006
    ..While more research is needed to understand the pathology of the metabolic syndrome, there is no ambiguity that physicians should treat cardiovascular risk factors in individuals with metabolic syndrome...